Rational Therapeutic Targeting of Oncogenic Immune Signaling States in Myeloid Malignancies

IN PARTNERSHIP WITH LEUKEMIA & LYMPHOMA SOCIETY AND THE PAUL G. ALLEN FRONTIERS GROUP (2020-PRESENT)

Dr. Starczynowski is investigating the role and potential benefit of therapeutic targeting of a protein called UBE2N in acute myeloid leukemia (AML).

BACK TO OUR PORTFOLIO